#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	4344	16S	1529	1529	100.0	16S.l15.c30.ctg.1	2337	535.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1442	1442	C	629	C,T	574,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6838	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3946	518.6	0	.	n	.	0	T695C	SNP	695	695	T	1185	1185	C	546	C	490	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6838	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3946	518.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1827	1827	A	605	A,T	557,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6838	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3946	518.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2461	2461	C	603	C	562	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6838	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3946	518.6	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3087	3087	T	603	T	546	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6838	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3946	518.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2535	2535	A	618	A	563	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	758	folP	852	852	100.0	folP.l6.c4.ctg.1	1959	115.7	1	SNP	p	R228S	1	.	.	682	684	AGC	1241	1243	AGC	151;151;151	A;G;C,A	136;136;134,1	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1280	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3694	103.5	1	SNP	p	S91F	0	.	.	271	273	TCC	754	756	TCC	101;100;100	T;C;C	89;89;91	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1280	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3694	103.5	1	SNP	p	D95G	0	.	.	283	285	GAC	766	768	GAC	100;100;100	G;A;C,T	89;89;89,1	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1280	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3694	103.5	1	SNP	p	D95N	0	.	.	283	285	GAC	766	768	GAC	100;100;100	G;A;C,T	89;89;89,1	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	574	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	2002	86.1	0	.	p	.	0	A39T	NONSYN	115	117	GCC	802	804	ACC	136;136;137	A;C;C	126;127;129	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	574	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	2002	86.1	0	.	p	.	0	R44H	NONSYN	130	132	CGC	817	819	CAC	139;139;139	C;A;C	128;130;130	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	574	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	2002	86.1	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	1000	1002	CAC	149;148;148	C;A;C	142;142;142	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	574	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	2002	86.1	1	SNP	p	G45D	0	.	.	133	135	GGC	820	822	GGC	139;139;139	G;G;C,A	131;126;128,1	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	394	mtrR_promoter	250	250	100.0	mtrR_promoter.l6.c17.ctg.1	1620	72.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1434	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3649	117.9	1	SNP	p	D86N	0	.	.	256	258	GAC	871	873	GAC	157;157;157	G;A;C	135;130;137	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1434	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3649	117.9	1	SNP	p	S87W	0	.	.	259	261	AGT	874	876	AGT	157;159;159	A;G;T	130;141;138	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1434	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3649	117.9	1	SNP	p	S87R	0	.	.	259	261	AGT	874	876	AGT	157;159;159	A;G;T	130;141;138	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1434	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3649	117.9	1	SNP	p	S87I	0	.	.	259	261	AGT	874	876	AGT	157;159;159	A;G;T	130;141;138	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1434	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3649	117.9	1	SNP	p	S88P	0	.	.	262	264	TCC	877	879	TCC	158;159;160	T,C,G;C;C	137,1,1;135;140	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1172	parE	1986	1986	100.0	parE.l15.c17.ctg.1	2950	118.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1691	1693	GGC	151;151;151	G;G;C	134;132;133	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	1082	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2939	110.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1620	1622	GCA	173;173;173	G,A;C;A	159,1;156;156	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1082	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2939	110.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1623	1625	ATC	173;175;176	A;T,C;C	156;156,1;156	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1082	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2939	110.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1635	1637	GTG	182;181;181	G;T;G	165;160;156	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1082	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2939	110.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1635	1637	GTG	182;181;181	G;T;G	165;160;156	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1082	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2939	110.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2139	2141	ACC	129;130;131	A,C;C;C	113,2;116;119	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1082	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2939	110.0	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2193	2195	GCG	133;131;131	G;C;G	117;108;111	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1082	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2939	110.0	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2193	2195	GCG	133;131;131	G;C;G	117;108;111	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1082	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2939	110.0	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2316	2318	GGC	133;133;133	G,T;G;C	112,1;118;115	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1082	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2939	110.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2325	2327	GGC	132;132;132	G,T;G;C	105,2;114;111	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1082	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2939	110.0	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2343	2345	CCG	140;141;142	C,G;C;G	109,1;117;111	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1440	ponA	2397	2397	99.96	ponA.l15.c17.ctg.1	3604	119.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	724	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2286	94.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	816	816	C	116	C	106	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	892	porB1b	1035	1035	96.01	porB1b.l15.c30.ctg.1	1826	143.1	0	.	p	.	0	E48K	NONSYN	142	144	GAA	551	553	AAA	188;190;190	A;A,C;A	170;170,1;172	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	892	porB1b	1035	1035	96.01	porB1b.l15.c30.ctg.1	1826	143.1	0	.	p	.	0	T87A	NONSYN	259	261	ACT	668	670	GCT	176;175;174	G;C;T,C	157;152;153,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	892	porB1b	1035	1035	96.01	porB1b.l15.c30.ctg.1	1826	143.1	0	.	p	.	0	G189S	NONSYN	565	567	GGC	974	976	AGC	160;161;161	A,G;G;C	140,2;149;152	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	892	porB1b	1035	1035	96.01	porB1b.l15.c30.ctg.1	1826	143.1	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1040	1040	T	162	T	152	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	892	porB1b	1035	1035	96.01	porB1b.l15.c30.ctg.1	1826	143.1	1	SNP	p	G120K	0	.	.	358	360	GGT	767	769	GGT	156;156;156	G,A;G;T	140,1;140;142	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	892	porB1b	1035	1035	96.01	porB1b.l15.c30.ctg.1	1826	143.1	1	SNP	p	A121D	0	.	.	361	363	GCC	770	772	GCC	158;158;157	G,T;C;C	135,1;139;137	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	892	porB1b	1035	1035	96.01	porB1b.l15.c30.ctg.1	1826	143.1	1	SNP	p	A121N	0	.	.	361	363	GCC	770	772	GCC	158;158;157	G,T;C;C	135,1;139;137	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	283	3064	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	5555	165.4	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2237	2239	AAT	177;177;179	A;A;T	163;162;166	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	564	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1571	107.2	1	SNP	p	V57M	1	.	.	169	171	ATG	664	666	ATG	219;219;219	A;T,A;G	199;197,1;200	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
